Notizie AIOM – anno XV n. 619

7 Marzo 2017

Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-analysis

Olanzapine is an anti-psychotic drug that has been used for preventing and treating Chemotherapy-Induced Nausea and Vomiting (CINV). This study aimed to systematically review and meta-analyze the efficacy and safety of olanzapine for prophylaxis and treatment of CINV. We ...
Leggi tutto

3 Marzo 2017

ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes

February 28, 2017 - As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients ...
Leggi tutto

3 Marzo 2017

ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers

February 28, 2017 - A new analysis of data from the U.S. Military Health System found that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital ...
Leggi tutto

3 Marzo 2017

FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

February 28, 2017 - The FDA has granted a priority review to a biologics license application (BLA) for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed after platinum-based therapy, according ...
Leggi tutto

3 Marzo 2017

Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union

March 2, 2017 - The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under this agreement, U.S. and EU regulators will be able to utilize each other’s good ...
Leggi tutto

3 Marzo 2017

Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes

Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but ...
Leggi tutto

3 Marzo 2017

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the ...
Leggi tutto

3 Marzo 2017

27 febbraio 2017 – Operatività dell’Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali

3 Marzo 2017

27 febbraio 2017 – Pubblicazione schede di monitoraggio Registro Blinatumomab

3 Marzo 2017

27 febbraio 2017 – Chiusura Registro di monitoraggio Panitumumab

LAVORIAMO CON

News

ICTUS, SCARSA QUALITÀ DELLA VITA NEL POST RIABILITAZIONE PER 1 PAZIENTE SU 4

SCOPERTE 74 REGIONI DNA LEGATE A METABOLISMO E CHILI DI TROPPO

BRISTOL MYERS SQUIBB OTTIENE L’APPROVAZIONE DELLA COMMISSIONE EUROPEA PER NIVOLUMAB NEL TRATTAMENTO ADIUVANTE DI PAZIENTI CON TUMORE ESOFAGEO O DELLA GIUNZIONE GASTRO-ESOFAGEA CON MALATTIA PATOLOGICA RESIDUA DOPO CHEMIO-RADIOTERAPIA

ACTO LOMBARDIA RINNOVA GLI APPUNTAMENTI CON “LA CASA DELLE DONNE”

ACTO PUGLIA PORTA “MOVIMENTO E SALUTE” IN REGIONE

CELGENE, ORA PARTE DI BRISTOL-MYERS SQUIBB, ANNUNCIA I RISULTATI PRELIMINARI DELLO STUDIO A LUNGO TERMINE CHE RAFFORZANO IL PROFILO DI EFFICACIA E SICUREZZA DI OZANIMOD NEI PAZIENTI CON FORME RECIDIVANTI DI SCLEROSI MULTIPLA

POLIAMBULANZA, 20 POSTI LETTO PER I PAZIENTI SUB ACUTI PRESSO LA RSA KORIAN “COSI’ PROVIAMO A SUPERARE I LIMITI IMPOSTI DALLA PANDEMIA”

Notizie AIOM – anno XV n. 619

Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-analysis

ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes

ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers

FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union

Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

27 febbraio 2017 – Operatività dell’Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali

27 febbraio 2017 – Pubblicazione schede di monitoraggio Registro Blinatumomab

27 febbraio 2017 – Chiusura Registro di monitoraggio Panitumumab